Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,054 matching trials from the live ClinicalTrials.gov search.
Conditions
Melanoma, Skin
Interventions
Scan with elastic scattering spectroscopy device to assess risk of malignancy
Device
Lead sponsor
DermaSensor, Inc.
Industry
Eligibility
40 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Smyrna Beach, Florida • Morehead City, North Carolina
Conditions
Melanoma
Interventions
GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, GM-CSF
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery, Trametinib
Drug · Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer, Lung Cancer, MMR-deficient Tumors, Breast Cancer, Pancreatic Cancer, Renal Cell Carcinoma (RCC), Solid Tumors, UC (Urothelial Cancer)
Interventions
Pembrolizumab, itacitinib, INCB050465
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more
Conditions
Melanoma
Interventions
Ipilimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Conditions
Cancer, Cancer (Solid Tumors)
Interventions
JMT108
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Huntersville, North Carolina • Dallas, Texas • Fairfax, Virginia
Conditions
Melanoma
Interventions
Nivolumab, Pembrolizumab, Radiation Therapy, Therapeutic Exchange Plasma, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Sentinel Lymph Node Biopsy, Breast Cancer, Melanoma
Interventions
pudexacianinium chloride
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Orange, California
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
aldesleukin, bryostatin 1
Biological · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Lebanon, New Hampshire • Richmond, Virginia
Conditions
Melanoma
Interventions
Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide)
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Interventions
HLX17, US-sourced Keytruda®
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years to 85 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more
Conditions
Advanced Tumors, Melanoma, Non-Small-Cell Lung Cancer, Erdheim-Chester Disease, Other RAS/RAF/MEK/ERK Mutated Tumors
Interventions
HH2710
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Lafayette, Indiana • Detroit, Michigan
Conditions
Melanoma
Interventions
Pimonidazole
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Recurrent Melanoma, Stage IV Skin Melanoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy
Biological · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Autologous CD8+ Melanoma Specific T Cells, Cyclophosphamide, Ipilimumab, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
Interventions
carboplatin, paclitaxel, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Conditions
Metastatic Melanoma
Interventions
Lifileucel (LN-144)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Melanoma
Interventions
Melanoma Reactive TIL, Cyclophosphamide, IL-2, Fludarabine, 1200 total body irradiation (TBI)
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Cancers
Interventions
Atorvastatin, Fish Oil Supplement, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Melanoma
Interventions
DC/tumor fusion vaccine
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Stage IV Melanoma, Recurrent Melanoma
Interventions
allogeneic lymphocytes, anti-thymocyte globulin, cyclophosphamide, fludarabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Melanoma (Skin)
Interventions
iodinated contrast dye, computed tomography, positron emission tomography, fludeoxyglucose F 18
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York